|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500105147 |
|
最近更新日期: Date of Last Refreshed on: |
2025-06-30 11:44:43 |
|
注册时间: Date of Registration: |
2025-06-30 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
沁神口腔护理液缓解牙周炎的有效性与安全性的随机、双盲、安慰剂平行对照临床试验 |
|
Public title: |
A Randomized, Double-blind, Placebo-controlled Trial on the Efficacy and Safety of Qinshen Mouthwash in Alleviating Periodontitis |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
沁神口腔护理液缓解牙周炎的有效性与安全性的随机、双盲、安慰剂平行对照临床试验 |
|
Scientific title: |
A Randomized, Double-blind, Placebo-controlled Trial on the Efficacy and Safety of Qinshen Mouthwash in Alleviating Periodontitis |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘显 |
研究负责人: |
刘显 |
|
Applicant: |
Xian Liu |
Study leader: |
Xian Liu |
|
申请注册联系人电话: Applicant telephone: |
+86 138 8076 0220 |
研究负责人电话: Study leader's telephone: |
+86 138 8076 0220 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
jssyliuxian@163.com |
研究负责人电子邮件: Study leader's E-mail: |
jssyliuxian@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
成都市武侯区人民南路三段14号 |
研究负责人通讯地址: |
成都市武侯区人民南路三段14号 |
|
Applicant address: |
No. 14, Section 3, Renmin South Road, Wuhou District, Chengdu, China |
Study leader's address: |
No. 14, Section 3, Renmin South Road, Wuhou District, Chengdu, China |
|
申请注册联系人邮政编码: Applicant postcode: |
610041 |
研究负责人邮政编码: Study leader's postcode: |
610041 |
|
申请人所在单位: |
四川大学华西口腔医院 |
||
|
Applicant's institution: |
West China Hospital of Stomatology, Sichuan University |
||
|
研究负责人所在单位: |
四川大学华西口腔医院 |
||
|
Affiliation of the Leader: |
West China Hospital of Stomatology, Sichuan University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
WCHSIRB-D-2025-323 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
四川大学华西口腔医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Institutional Review Board, West China Hospital of Stomatology, Sichuan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-06-12 00:00:00 |
||
|
伦理委员会联系人: |
李灏来 |
||
|
Contact Name of the ethic committee: |
Haolai Li |
||
|
伦理委员会联系地址: |
成都市武侯区人民南路三段14号 |
||
|
Contact Address of the ethic committee: |
No. 14, Section 3, Renmin South Road, Wuhou District, Chengdu, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 28 8550 1479 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
四川大学华西口腔医院 |
||||||||||||||||||||||
|
Primary sponsor: |
West China Hospital of Stomatology, Sichuan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
成都市武侯区人民南路三段14号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 14, Section 3, Renmin South Road, Wuhou District, Chengdu, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
GCP课题 |
||||||||||||||||||||||
|
Source(s) of funding: |
GCP Research Project |
||||||||||||||||||||||
|
Target disease: |
Periodontitis |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
I期临床试验 | ||||||||||||||||||||||
|
Study phase: |
1 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
评价沁神口腔护理液缓解牙周炎的有效性和安全性。 |
||||||||||||||||||||||
|
Objectives of Study: |
Assessment of the Efficacy and Safety of Qinshen Mouthwash in Alleviating Periodontitis. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄18-70岁,性别不限; 2.根据 2018 牙周病新分类诊断为Ⅰ/Ⅱ期A/B级牙周炎; 3.口内至少存在 20 颗天然牙,Ramfjord指数牙(即16牙、21牙、24牙、36牙、41牙、44牙)为天然牙,无缺失、非残根; 4.具备良好的视力、肢体运动及判断能力,且自愿参加试验并签署知情同意书,能配合完成试验。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Age 18-70 years old, gender is not limited; 2. Diagnosed with stage I./II grade A/B periodontitis according to the 2018 new classification of periodontal disease; 3. At least 20 natural teeth are present in the mouth, and Ramfjord index teeth (i.e., 16 teeth, 21 teeth, 24 teeth, 36 teeth, 41 teeth, 44 teeth) are natural teeth, no missing and non-residual roots; 4. Have good vision, limb movement and judgment ability, and voluntarily participate in the trial and sign the informed consent form, and be able to cooperate with the completion of the trial. |
||||||||||||||||||||||
|
排除标准: |
1.对本次试验所用产品任何成分有自我报告过敏史者; 2.孕妇及哺乳期妇女; 3.近3月内进行过洁治、刮治等牙周治疗者; 4.近14天内使用过激素、抗生素等药物者; 5.肝功能损害或肾功能不全者; 6.存在甲状腺机能异常、血液疾病、急性病毒性口炎、创伤性溃疡、神经系统疾病、精神系统疾病等; 7.同时参加了其他临床试验且未达到临床终点,或近3个月内参加过其他临床试验; 8.无法完成或配合试验流程者。 9.其他研究者认为不适合纳入临床研究的情况。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Those who have a history of self-reported allergies to any of the ingredients used in this trial; 2. Pregnant and lactating women; 3. Those who have undergone periodontal treatment such as cleaning and scaling in the past 3 months; 4. Those who have used hormones, antibiotics and other drugs in the past 14 days; 5. Patients with liver impairment or renal insufficiency; 6. Abnormal thyroid function, blood diseases, acute viral stomatitis, traumatic ulcers, nervous system diseases, psychiatric diseases, etc.; 7. Participated in other clinical trials at the same time and did not meet the clinical endpoints, or participated in other clinical trials in the past 3 months; 8. Those who are unable to complete or cooperate with the test process. 9. Other situations that are considered by the investigator to be unsuitable for inclusion in clinical studies. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-07-01 00:00:00至 To 2026-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-07-01 00:00:00 至 To 2026-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
随机表存储在一个安全的并限制访问文件夹。随机表的副本将被发送给的负责产品分配和产品应用培训的工作人员手中。在随机化过程中,应打印该副本以便在研究中心完成随机化。随机化ID和相应的治疗应转录到研究病例报报告表(CRF)中。指定的研究中心人员负责保持随机化的完整性和设盲。原始填写完整的列表应保留在研究中心主文档中,供监查员审查,以确保其依从性。一旦完成研究,随机表将被合并到数据库进行数据分析。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The randomization list shall be securely stored in an access-restricted folder, with a copy provided to personnel responsible for investigational product allocation and administration training. During the randomization process, a printed copy shall be utilized at the study site. Randomization IDs and corresponding treatments must be accurately transcribed into Case Report Forms (CRFs), with designated site staff maintaining randomization integrity and blinding procedures. The original completed list shall be retained in the site master file for monitor verification to ensure compliance, and will ultimately be incorporated into the database for statistical analysis upon study completion. This procedure ensures proper documentation while preserving blinding throughout the trial in accordance with ICH-GCP guidelines for clinical trial management. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
双盲 |
|
Blinding: |
Double Blind |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
知情同意书及随访文书记录统一专柜管理,电子数据专门电脑记录管理。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Informed consent forms and follow-up documentation shall be stored in a designated locked cabinet, while electronic data shall be managed through a dedicated computer system. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |